**BUILDING & VALIDATING ARIA CHEMOTHERAPY AND SUPPORT REGIMENS**

**Objective**

The purpose of this Standard Operating Procedure (SOP) is to describe the procedure to be followed when building and validating adult and paediatric chemotherapy or other SACT regimens (referred to as chemotherapy regimens) and symptom management plans (referred to as support regimens) in the ARIA electronic prescribing system (referred to as ARIA).

**Scope**

This SOP applies to all adult and paediatric chemotherapy and support regimens including clinical trials

**Responsibilities**

* + The ARIA system administrator is responsible for allocating and overseeing the building and validation of all chemotherapy and support regimens in ARIA and storing all associated documents.
  + Only specialist pharmacists and technicians who have received full training on the use of ARIA are authorised to build regimens in Planner.
  + All regimens must be built in the Planner app of ARIA and reviewed in Manager by the builder to identify and correct any errors prior to validation
  + All regimens must be fully tested and validated by a pharmacist (other than the builder), consultant and nurse (excluding clinical trials) who have received full training on the use of ARIA and are authorised to validate regimens before they can be approved for use.
  + All regimen amendments must be re-validated by a pharmacist (as a minimum) before they can be approved for use.
* The pharmacist validation should be completed in 2 stages with Planner checked first, then the consultant and nurse complete their validation, then the validating pharmacist completes the validation in Manager
  + The consultant validation (which must be undertaken by the Principal Investigator for clinical trials) will check the regimen details and prescribing functions in Manager. Consultants will need to use a new test patient for validation.
  + The nurse validation will check the regimen for any nursing/administration-related issues in Manager. Nurses will need to use the same test patient used by the validating consultant. For clinical trials regimens, this stage will be omitted.
  + Any errors detected by the validating pharmacist in Planner must be referred back to the regimen builder for correction. Any errors detected by the validating consultant or nurse should be referred back to the validating pharmacist who should faciltate correction. Once corrected, the regimen must be tested again to ensure that the errors have been rectified. If a simple error is found, this can be rectified and re-checked at any time before approval. If a complex error is found that will impact on the rest of the validation procedure, the error must be rectified before continuing with the rest of the validation procedure.
  + Each checklist must be signed by the validator to indicate a successful validation of the regimen and returned to the KMCC adminstrator and system administrator
  + The validation paperwork for all regimens made live on ARIA must be sent to the KMCC administrator and system administrator for storage in the document management system
  + ALL regimens on ARIA will be made live by the KMCC system administrator. In their absence, an appropriately trained pharmacist will need to make the regimen live.

**Reference Sources**

Ensure that you have access to the following, as you will require them during the regimen build & validation:

* K&M SACT protocol or other reference document for the regimen.
* KMCCEP006 ARIA regimen classification guide for adult regimens

**PROCESS**

**Building a Regimen**

Before starting the build, ensure all the drugs you require are present in the ARIA formulary. If they are not, request them on form **KMCCEP007 Adding, amending & deleting agents from the ARIA formulary** from system administrator. If you are unsure, contact the system administrator.

You can then choose to do one of the following:

1. **Build a new regimen from scratch**: Select “New” button to open up the “New Plan” window.
2. **Amend a regimen**: An existing regimen should be updated using the Amend button wherever possible however, if the Amendments Mandatory tick box is selected then **DO NOT AMEND** the regimen. Instead, click the “Copy” button and untick the Amendments Mandatory option, before proceeding with the changes.
3. **Copy a regimen:** Select this option if updating an approved regimen that has Amendments Mandatory ticked or if you wish to use the existing regimen to build a similar one.

If you are unsure which option to choose, refer to the system administrator for advice. On completion of the regimen, complete, sign and submit the building checklist to the validating pharmacist. If the validating pharmacist has not yet been assigned, send to the ARIA system administrator.

**Validating a Regimen**

* The pharmacist validation must be undertaken by a pharmacist other than the builder. The first part of the validation checks the regimen build in Planner.
* The consultant validation must be performed by a consultant specialising in the tumour site that the regimen treats. The validation checks the regimen details and prescribing functions. Consultants will need to use a different test patient for validation.
* The nurse validation must be performed by a specialist chemotherapy or oncology nurse. The validation checks the regimen for any nursing/administration-related issues. Nurses will use the same test patient as the validating consultant. This step is not performed for clinical trials regimens
* The pharmacist validation then continues. The second part of the validation checks the regimen build in Manager
* Each checklist must be signed by the validator to indicate a successful validation of the regimen and returned to the KMCC system administrator
* For clinical trial builds; validation will be done by the clinical trial pharmacist or specialist pharmacist who is overseeing the setup of the study. This is immediately followed by a validation by Principal Investigator (consultant leading on the study). There is no validation carried out by a nurse for clinical trial builds. Checks must be performed in the same way as for non-clinical trial builds with the nuances of the study being validated by a person well versed in the clinical trial protocol.

**Approving a Regimen for use**

* For all regimens, once completed, the validation checklists and all associated documentation should then be forwarded to the KMCC administrator.
  + ALL regimens on ARIA will be made live by the KMCC system administrator. In their absence, an appropriately trained pharmacist will need to make the regimen live. In all cases the SOP KMCCEP004 will be followed to complete the go-live process

**Limitations**

Inpatient haematology regimens which include complex hydration and/or drugs to be administered continuously across more than one calendar day cannot be built in ARIA. Such treatments should be available as a paper protocol for prescribing for individual patients. Refer to KMCC system administrator for guidance if needed. Ensure that the total duration of the Internal agents does not exceed 10 hours a day for day case regimen

|  |  |
| --- | --- |
| **ARIA PLANNER** | |
| **LOG IN TO PLANNER:** ENSURE THAT BOTH THE “FROM” AND “LOGIN TO” BOXES HAVE “MTW NHS TRUST” SELECTED FROM THE DROPDOWN MENUS.  **OPEN PLAN WINDOW:** IF THIS DOESN’T AUTOMATICALLY OPEN THEN SELECT “FILE - OPEN PLAN”. THE OPEN PLAN WINDOW LISTS ALL REGIMENS THAT HAVE ALREADY BEEN BUILT UNDER THE PLAN TYPE SELECTED IN THE DROP-DOWN MENU. THE STATUS COLUMN WILL INDICATE WHETHER THEY ARE PENDING (I.E. STILL BEING BUILT), IN TESTING OR APPROVED.  **BUILDER: SELECT NEW, AMEND OR COPY AS NECESSARY (SEE ABOVE FOR GUIDANCE)**  **VALIDATOR: BEFORE COMMENCING VALIDATION, ENSURE YOU ARE IN RECEIPT OF A COMPLETED BUILDING CHECKLIST, THEN DOUBLE CLICK ON THE REGIMEN YOU REQUIRE THEN SELECT ‘DEFINITION’ FROM THE TOOL BAR** | |
| **DO NOT COPY AND PASTE TEXT FROM WORD DIRECTLY INTO ANY WINDOW IN ARIA AS THIS WILL CAUSE A SYSTEM ERROR. INSTEAD, COPY FROM WORD INTO NOTEPAD THEN FROM NOTEPAD INTO ARIA. TABLES AND DIAGRAMS, SHOULD NOT BE ENTERED INTO ARIA, INSTEAD, REFERENCE SHOULD BE MADE TO WHERE THEY CAN BE VIEWED E.G. K&M SACT PROTOCOL** | |
|  | **NEW PLAN WINDOW** |
|  | **Definition tab** |
| **1.1.1.** | **Plan Name**: This box can only contain up to 20 characters and must be unique. The K&M SACT protocol number must be entered. On leaving the new plan window, this can then not be changed so ensure it is entered correctly.  **1.1.1**  **1.1.3**  **1.1.2**  **1.1.4**  **1.1.5**  **1.1.6**  **1.1.7**  **1.1.8**  **1.1.9**  **1.1.10**  **1.1.11**  For Clinical Trials the plan name should be a short-hand identifier for the trial, regimen name and/or arm. |
| **1.1.2.** | **Version**: The version number in this box will be automatically created and updated by ARIA. |
| **1.1.3.** | **Display Name**: This box will allow you to enter more information than the plan name box (80-character limit). This name is displayed in most user windows in Manager. The K&M SACT protocol number must be entered first followed by the protocol name, e.g. BRE-009 FEC75 (refer to protocol or KMCC regimen list). For new regimens that do not yet have a protocol number, one will be created by KMCC team. The protocol name should be entered in normal sentence case unless the regimen name is an acronym, e.g. CTD. For off-protocol/non-NOG approved, the display name will be assigned by the ARIA system administrator.  For Clinical Trials the Display name must include the trial short title with word “Clinical Trial” as a suffix, the Arm name (if relevant) and regimen name e.g. ICON-9 clinical trial - Arm 1 – Olaparib + Cediranib Maintenance. |
| **1.1.4.** | **Plan Type**: Select “Regimen” if you are building a chemotherapy regimen. Select “Symptom Mgmt” if you are building a support regimen. For Clinical Trials all builds will be ‘Regimen’ unless there is a specific need for a trial specific symptom management build. The need for this must be decided by the Principal Investigator and Clinical Trial Pharmacist. |
| **1.1.5.** | **Sponsor**: Select “Internal” from dropdown box. |
| **1.1.6.** | **Owner**: Select “MTW NHS Trust” from dropdown box. |
| **1.1.7.** | **Brief Description**: Enter “See Plan Summary”. |
| **1.1.8.** | **External Name**: Leave this box blank. |
| **1.1.9.** | **Plan group**: Leave this box blank |
| **1.1.10.** | **Amendments Mandatory** (chemotherapy regimens only): This box must be left unticked for all standard regimens including clinical trials. When ticked, any future amendments to the regimen will be applied to all patients being treated with the regimen, including those patients already prescribed the regimen. |
| **1.1.11.** | **Clinical Trial**: Tick If building a Clinical Trial regimen; the phase of the trial should also be selected from the dropdown. |
|  | **Classification tab** |
| **1.2.1.** | **Sex**: Ensure “N/A” radio button is selected when building, this appears blank when validating  1.1.3 |
| **1.2.2.** | **Age Range**: Leave all boxes blank. |
| **1.2.3.** | **Classification:** In the classification box, click on the “Add” button on the right then:  **1.2.1**  **1.2.2**  **1.2.3**   * For chemotherapy regimens – All regimens will need a disease site but not all wil require a cancer category. Refer to *KMCCEP006 Regimen classification specification – Disease site and cancer categories* document for instructions on which are required for your regimen. Select “Disease Site” from the Classification dropdown box then the relevant cancer disease site(s) from the Value dropdown box. If the regimen is used to treat more than one disease site, this process must be repeated for everydisease site. If the disease site has a sub-category, e.g. NSCLC, this also needs to be added by selecting “Cancer Categories” from the Classification dropdown box then selecting the relevant sub-category from the Value dropdown box * For support regimens - Select “Problems” from the Classification dropdown list then select the relevant symptom from the “Value” dropdown list. * For Clinical Trial regimens - The disease site should be selected the same as standard builds as above. When selecting Cancer Categories for clinical trials, the ‘Clinical Trials –…’ category must be selected for the disease area the clinical trial is studying. e.g. a CT NSCLC lung cancer regimen would have the categories: Disease Site – Lung and Cancer Category – Clinical Trial NSCLC. |
|  | **Authors tab:** Leave blank. |
|  | **Authorized Users tab:** This will contain the name of the regimen builder. Other authorised users must be added by clicking on the “Add” button on the right. The following users must be added: Caroline Waters, Hayley Paddock, Michelle Archer and Helen Downs, as well as the Varian access user Ks VMS. The validating pharmacists name should NOT appear in this tab at this stage. Contact the system administrator and ask to be removed from the list should your name be present before continuing |
|  | **Medical Management tab (chemotherapy regimens only)** |
| **1.5.1.** | **Component**: This is usually left blank, unless specific deviations are required from Security set-up, e.g. for clinical trials. This setting may be used to specify different settings, e.g. for GFR. BSA is capped in Security for all regimens at 2m2. It is not possible to set a different BSA cap or to uncap a regimen in this window  **1.5.2**  **1.5.1** |
| **1.5.2.** | **Classification Scheme**: This setting cannot be changed after clicking ‘OK’, so ensure that you select the correct one at this stage. For non-trial regimens Add Toxicity Grading scheme of “NCI CTCAE v4.0 SI”.  For clinical trial regimens use the CTCAE version referred to in the protocol. If the protocol CTCAE version is not available on ARIA, the latest version of CTCAE on ARIA must be used.  **1.5.3** |
| **1.5.3.** | **Calculation Formula**: This box is used to select a specific formula for BSA or GFR calculation for a regimen that will override the standard formulae set up in the Security module. The default formulae set up at Security level are Cockcroft & Gault for GFR calculation and Mosteller for BSA calculation. Other formulas may be required for clinical trial regimens where this has been previously agreed with PI in line with a clinical trial protocol. |
|  | **Medical Management tab (support regimens): Leave blank.** |
|  | **Sponsor tab:** Leave blank. |
| **BUILDER**: SELECT OK TO COMPLETE AND EXIT **VALIDATOR**: SELECT CANCEL TO LEAVE WINDOW  CLICK ON ‘GO TO’ IN PLAN AGENDA SCREEN | |

|  |  |
| --- | --- |
|  | **VIEW/MODIFY PHASE WINDOW** |
| **2.1.** | **Phase**: Automatically numbered as “1”. |
| **2.2.** | **Phase Name** **(chemotherapy regimens)**: Leave as “Phase 1”. |
| **2.3.** | **Phase Name** **(support regimens)**: This is the name the prescriber will see when they select the regimen. Enter the name of the support regimen here. Maximum 20-character limit |
| **2.4.** | **Purpose**: Leave blank. |
| **2.5.** | **Service Type**: Leave blank |
| **2.6.** | **Modality**: Select “Radiation” for chemo-radiation regimens. Leave blank for all other regimens.  **2.1**  **2.2 + 2.3**  **2.4**  **2.5**  **2.6**  **2.7**  **2.8**  **2.9**  **2.10**  **2.11**  **2.12**  **2.13**  **2.14** |
| **2.7.** | **Toxicity Causes Required**: Leave this box unticked.  **2.15\*\*** |
| **2.8.** | **Closed to Accrual**: Leave this box unticked. |
| **2.9.** | **Schedule Type**: “Cyclical” should be selected for most chemotherapy and support regimens that are repeated at regular intervals for a given number of cycles. “Linear” applies to treatment courses consisting of a single cycle that will not be repeated. “Linear – Neg. Days” should only be selected for bone marrow transplant regimens or any other regimens that may require treatment on negative day numbers. If “Linear – Neg. Days” is selected, enter the Starting Day for the cycle, e.g. Day -5, instead of the Number of Cycles. |
| **2.10.** | **Number of Cycles**: Specify the number of cycles required for the regimen.  If the KMCC SACT protocol states a range for number of cycles where treatment is for a single indication, select the most commonly used number of cycles unless the regimen is for chemoradiotherapy where the higher number of cycles should be entered.  Regimens for a single indication with a fixed duration, e.g. trastuzumab 18 cycles, should be set up for the full course.  Regimens with multiple indications of varying cycle numbers, should be set up for the lowest number of cycles  Treatments which continue until disease progression set up as duration of 12 months |
| **2.11.** | **Cycle Length (days)**: Specify the cycle length (in days) required for the regimen. If the Kent & Medway SACT proforma does not specify the length of a cycle (e.g. some haematology regimens), set cycle length as 28 days. If the protocol states a cycle length of 30 days, the regimen must be built as a cycle length of 28 days so that subsequent cycle treatment days are scheduled for the same day of the week and do not fall on a weekend. A protocol would usually only specify a duration of 30 days if the pack size of the treatment contained 30 days’ supply, e.g. erlotinib. If this is the case, then a note should be added to the Admin tab textbox (see 4.2) when building the agent stating “DISPENSE 30 DAYS SUPPLY”. For clinical trials refer to the clinical trial protocol for cycle length. If the protocol has varying cycle lengths then a different regimen should be built for each cycle(s) that are different. e.g. induction cycles of 28 days, consolidation cycles of 21 days and maintenance cycles of 28 days. |
| **2.12.** | **Maximum Drift (days)**: Leave as “0” days. |
| **2.13.** | **Toxicity Risk scores**: Leave blank |
| **2.14.** | **Description box**: Leave blank |
| **2.15.** | **Chemo Order Instructions**: Leave blank. \*\* This function is not normally found in this location |
| SELECT OK TO SAVE AND CLOSE THE WINDOW  DOUBLE-CLICK ON AGENTS TO OPEN THE AGENTS WINDOW. SELECT ‘NEW’ TO ADD AN AGENT | |

|  |  |
| --- | --- |
|  | **AGENTS** |
| **Add NB Monitoring parameters as the first agent then add subsequent drugs as per the order of administration on the reference document and their agent category, without regard for the day they are due as this will be set later in scheduling. Add all pre-meds first, then all treatment drugs, then all TTO drugs. When adding the agents, bear in mind that the lower the number, the higher the place the drug will appear when prescribed so a drug in position 2 will appear for administration before the drug in position 3 if scheduled on the same day** | |
| **3.1.** | **Agent Selection**  Leave the “Formulary Only” box ticked and then type in the first 3 letters of the agent name. All matching entries will be listed in the Agent box (those in upper case are from First Data Bank whereas agents in lower case have been created manually and will not have interaction/allergy functionality). “NB Monitoring parameters” should be the first agent as the essential prescribing and monitoring guidance must be entered in the Admin tab textbox (see 4.2). When building a Clinical Trial regimen, the NB monitoring parameters should only specify the location of the local reference protocol for the regimen, it is not necessary to also enter the details into the ARIA agent. Select required agent from the list then click OK. This will take you to the Add Agent window. Ensure that the total duration of the Internal agents does not exceed 10 hours a day for day case regimen  Add subsequent agents ensuring they will appear in the correct order in Manager and include all pre-medications and supportive medicines that are required. If an agent will be required more than once in a regimen, e.g. vinorelbine day 1 and day 8, then this should be added once as a single entry where possible and scheduled twice for day 1 and day 8. There may occasionally be instances where an agent must be built more than once within a regimen, e.g. if the dose is different depending on the day of treatment. When adding agents for clinical trials, all Investigational Medicinal Products (IMP) supplied or reimbursed by the sponsor must include the suffix (Trial). e.g. Lenalidomide (Trial). If the required agent is a novel drug not on the formulary or is on the formulary and does not have the suffix (Trial) then a KMCCEP013 form must be completed and sent to the KMCC e-prescribing team for adding to the system. For all non-IMPs or standard of care stock, the standard agent file should be used.  Agents should be added multiple times to a regimen when different strengths/ doses are required; to enable each strength or dose be scheduled at the right times within the regimen.  **NB notes:** NB Notes are used to add information to the regimen that is on the protocol but not necessarily attached to a single drug. The only NB notes in use are NB Monitoring parameters (see above for guidance on required information) and NB Reminder for all other information e.g. pre-and post treatment line flushes, details of observation period between treatment drugs. An NB Reminder note should be added for all protocol instructions that are not attached to an agent, see screenshot below as an example of the protocol layout and how it is then built in ARIA. |

|  |  |
| --- | --- |
| **4.** | **ADD/VIEW / MODIFY AGENT** |
| **4.1.** | **Details Tab** |
| **4.1.1.** | **Agent Name**: This will show the agent name as selected on the previous screen. |
| **4.1.2.** | **Form**: The drug form will automatically be selected from the dropdown box, based on your previous selection from the formulary. This field should not be amended. |
| **4.1.3.** | **Take as Directed**: Whenever possible this box should be left unticked as ticking this box disables the dose/range and unit boxes so doses will not be calculated. Circumstances when the box will have to be ticked include drugs with variable doses, e.g. metoclopramide TDS for 3 days then PRN. When the box is ticked, full instructions regarding dose, frequency, duration and administration day would then need to be typed in the Admin tab textbox (see 4.2).  **4.1.1**  **4.1.2**  **4.1.4**  **4.1.3**  **4.1.5**  **4.1.6**  **4.1.7**  **4.1.8**  **4.1.9**  **4.1.10**  **4.1.11**  **4.1.12**  **4.1.13**  **4.1.15**  **4.1.14** |
| **4.1.4.** | **Agent Placeholder**: Leave this box unticked. |
| **4.1.5.** | **Dose**: Always leave the “Fixed Dose” radio button selected then enter the required dose. Filgrastim must be built as a ‘Fixed dose’ of 5mcg/kg. A dose banding table has been applied in Security to band the dose to 300mcg or 480mcg, as appropriate. Carboplatin should be set up with the dose unit selected as “AUC (CrCl)”. Prescribers will manually amend to “AUC (EDTA)” at the prescribing stage if/when an EDTA result is available. Vincristine for adult patients should be set as a flat dose of 2mg for all regimens that currently stipulate a calculated dose of 1.4 or 1.5mg/m2 (the calculated dose must be entered in the admin notes). Vincristine for paediatric patients should be built as per reference protocol. 5-FU pumps should be set up with the total dose to be infused as mg/m2 with the duration entered in the infusion mode duration box below. NB notes should be set up as a ‘Fixed Dose’ of 1, with the Unit dropdown box left blank and the Route dropdown box should be set as “Not Assigned”. |
| **4.1.6.** | **Dose/Range**: Enter the dose in the first Dose/Range box or for a range, enter a value in each box to show dose from and dose to. |
| **4.1.7.** | **Unit**: Enter as per protocol e.g. mg/kg, mg/m2, etc. |
| **4.1.8.** | **Route**: This will auto-populate based on the settings for the chosen drug and MUST NOT be altered. |
| **4.1.9.** | **Strength dropdown box** is usually left blank and cannot be manually entered. The box is only populated if the drug had more than one strength available during agent selection e.g. Co-codamol 8/500 or 30/500 |
| **4.1.10.** | **Rounding**: Leave the rounding boxes blank unless the protocol specifies a different rounding or banding schedule should be used. Dose banding tables should be added to all Cytarabine Injection entries where the standard dose is calculated. Cytarabine infusion entries are already banded at Security level. To add a different banding or rounding schedule, select “Dose Banded” from the Rounding Method dropdown box, then click on the red icon and click on the “Add” button to add each line of the dose banding table as required (see KMCCEP029 Adding dose banding tables to ARIA). |
| **4.1.11.** | **Maximum Single Dose**: A value should be entered here if specified on the protocol and if the agent is not a flat dose. For dose banded drugs, ensure the maximum dose corresponds to a dose band as per the entry in Security. If not, the equivalent dose band should be entered here, with a note added to the admin tab that the protocol maximum dose is NNmg, banded to NNmg on ARIA. Refer to KMCC system admin if unsure. Maximum single doses should not be entered for drugs marked as ‘Take as directed’. |
| **4.1.12.** | **Prescription Type**: Select “Internal” for all preparations that are administered on the ward. Select “Pickup - Internal” for all preparations that are to be supplied to the patient to take home. If Pickup - Internal is selected, leave Record Dose dropdown box as “No Dose Recordings” and leave Refill box unticked. For regimens with ‘Internal’ agents, “NB Monitoring Parameters” must be designated an ‘Internal’ agent. For regimens with only ‘Pickup - Internal’ agents, “NB Monitoring Parameters” must be set up as a ‘Pickup - Internal’ agent. |
| **4.1.13.** | **Sequence Number**: The sequence number will determine the order of administration for all drugs entered for the regimen. Where possible, an agent should be entered once when building the regimen and then scheduled for the appropriate days in Schedule Events window. If you are building a regimen where the same drug appears multiple times, e.g. cytarabine, BD for 10 days, for ADE, the sequence number may not be the same for every dose, depending on when other drugs are given. Therefore, it may be necessary to build an agent more than once so that each has a different sequence number. E.g. cytarabine would be built twice – once for am dose and once for pm dose – to allow other drugs to be inserted between the two doses. If you forget to add in a drug during your regimen build, all subsequent sequence numbers must be amended in reverse order before the drug can be added in at the vacant position. If building a clinical trial and adding multiple strengths of the same drug to facilitate titration these should be added consecutively in the relevant sequence in order to ensure they appear on ARIA correctly when scheduled. |
| **4.1.14.** | **Agent Category (chemo regimens only)**: Select the correct category for the drug from the dropdown list, e.g. treatment, hydration, etc. When adding an NB note, select “Not Applicable”. |
| **4.1.15.** | **Substitution Allowed?**: Leave the Yes radio button selected. |
| FOR INFUSIONS/INJECTIONS A SET OF BOXES WILL APPEAR, CONTINUE TO POINT 4.1.16 FOR INSTRUCTIONS ON COMPLETION. FOR ALL OTHER PREPARATIONS, GO TO POINT 4.2. | |
| **4.1.16.** | **Infusion Mode**: Selected from the dropdown box: “continuous” should be selected for infusions and “bolus” selected for bolus injections. If infusion mode is not clearly specified on SACT protocol, use “bolus” for durations of less than 10 minutes and “continuous” for durations of 10 minutes or greater.  **4.1.16**  **4.1.17**  **4.1.18**  **4.1.19**  **4.1.20** |
| **4.1.17.** | **Duration**: Enter duration of infusion (where required). The first box is where the numerical field is entered and the second dropdown box is where the units are selected. If the SACT protocol specifies a range for the infusion duration, e.g. bevacizumab, then this field should be left blank and the full infusion details entered in the Admin tab textbox (see 4.2). For 5-FU pumps, enter the infusion mode and duration in hours or days.If you decide to delete the infusion mode or duration after entering, select the ‘eraser’ icon to the right of the dropdown box. |
| **4.1.18.** | **Diluent and Volume**: These should be selected from the dropdown boxes if required. If the SACT protocol specifies a range for the diluent volume, e.g. oxaliplatin, then this field should be left blank and the full infusion details entered in the Admin tab textbox (see 4.2).  The Rate field is automatically calculated if both the duration and volume fields have been populated. |
| **4.1.19.** | **Diluent ID**: This box must be completed with a number if a diluent is required. This number should be sequential in terms of the order that the agents are administered in. If two or more agents are to be diluted and administered in the same infusion bag then each agent should be given the same Diluent ID number. |
| **4.1.20.** | **Line Number**: This box should be left blank unless the regimen states a specific line that the drug needs to be administered by if a double or triple lumen line is used and drugs are incompatible. |
| **4.2.** | **Admin tab** |
| **4.2.1.** | Additional administration instructions should be entered here as stated on the KMCC SACT protocol.   * For ALL drugs marked as ‘Take as directed’, enter FULL directions in this field, as specified in the KMCC SACT treatment protocol. * For all other drugs, ensure that no information is duplicated in the admin tab that will be provided by the scheduling or details tab (e.g. dose, frequency, duration). * For oral chemotherapy drugs with treatment days followed by a rest period within a single cycle, this should be stated in the admin tab as ‘Regimen standard schedule……’ * For ALL vinca alkaloid agents the following must be stated: “FOR INTRAVENOUS USE ONLY. FATAL IF GIVEN BY ANY OTHER ROUTE.” * For filgrastim and other drugs to be started after day 1, enter the actual start day in the admin instructions. * Administration times for in-patient regimens should be entered here, if appropriate, e.g. T=0. * Do not enter any information in tabular form. * If a maximum dose is specified in the agent details this must also be stated in the admin instructions. * The original vincristine dose, e.g. 1.4mg/m2, must be entered in this section in all cases where vincristine has been built as a flat dose of 2mg. * For drugs with a specified brand e.g. biosimilars, ensure a line is entered for staff to enter the brand supplied * For TTO drugs which on the protocol state ‘Dispense on cycle 1 then only if required’, this statement must be added to the admin tab * For clinical trials, specific details as per protocol must be added for each study medication. In addition to this pharmacy details for dispensing should be added here as well if accountability logs or specific vial/kit/pack must be selected. e.g. Pharmacy: Select specific vial numbers and complete accountability log. |
| **4.3.** | **Course tab:**Leave blank. |
| SELECT OK TO COMPLETE AGENT THEN REPEAT POINT 4 AS NECESSARY UNTIL ALL REQUIRED AGENTS HAVE BEEN ADDED THEN SELECT CLOSE TO RETURN TO THE PLAN AGENDA | |
| **4.4.** | **Reminders (support regimens only):** Leave blank |
| DOUBLE-CLICK ON SCHEDULE EVENTS TO ENTER SCHEDULE EVENTS WINDOW. | |
|  | **SCHEDULE EVENTS** |
|  | **Schedule Events Window**  **5.1.1.**  **5.1.2.**  **5.1.3.** |
| **5.1.1.** | **Starting On box**: The dropdown box should be left blank at this point. If specific days are selected in the scheduling agents window then the start day will be automatically entered here  (see 5.2.2). |
| **5.1.2.** | **View box**: Cycle Day radio button should always be selected. |
| **5.1.3.** | **Maintain box**: Schedule radio button should always be selected. |
| EACH AGENT NOW NEEDS TO BE SPECIFIED AS TO WHICH DAYS IT WILL NEED TO BE GIVEN ON. CLICK ON THE RELEVANT TREATMENT DAY BOX ALONGSIDE THE FIRST AGENT AND THEN CLICK THE ADD BUTTON TO OPEN THE ADD EVENT WINDOW. | |
|  | **Add Event** |
| **5.2.1.** | **Frequency and Duration**: These should be selected from the relevant dropdown boxes (disabled for “Take as directed” drugs). Do not use the frequency “mane”, as it will cause a system error, instead use ‘every am’. All other dropdown boxes are usually left blank.   * The PRN box may be ticked if required (disabled for “Take as directed” drugs) and Quantity can also be specified if necessary. * Internal agents, given as a single dose per day, must be scheduled as a separate event for each day that treatment is to be administered, e.g. ‘Once for 1 doses’, ‘bd for 1 day’ etc. including 5-FU pumps which must be scheduled ‘once’ for ‘1 doses’ on day 1. * TTO drugs that start on a day other than day 1 must always be scheduled on day 1 for the specified duration, irrespective of the actual start day to enable them to be marked as given to the patient. The actual start day can then be stated in the Admin tab including Filgrastim which must be scheduled OD on day 1 for the specified duration - or 5 days, if not specified – irrespective of the actual start day. * TTO drugs which are dispensed PRN should be scheduled for all cycles and a note added to the Admin tab the dispense on cycle 1 then only if required. * Within Clinical Trial builds NB monitoring parameters should be scheduled for each day the patient is to attend site for administration to ensure trial specific checks are done each time. |
| **5.2.2.** | **Days of Week**: Select appropriate day(s) of the week from the drop-down list (Pick-up Internal drugs only). Once selected, an additional box will appear at the bottom of the screen to select the ‘Starting on’ day. Select Monday in all cases. This will then also appear in the ‘Schedule Events’ window. |
| **5.2.3.** | **Cyclical tick box**: If treatment will not be repeated every cycle, un-tick the Cyclical tick box and specify cycle number that treatment will be given on. For TTOs that are dispensed on cycle 1 then only if required, schedule as cyclical to enable these to be dispensed at any cycle, as required. Non-cyclical drugs can be added to more than one cycle by clicking on the “Add” button that appears at the bottom once the cyclical tick box is un-ticked. If any part of an agents scheduling will be non-cyclical then all the events for that agent will need to be non-cyclical. For example: If a drug is required on day one of all cycles but only on day 8 of cycles 1 & 2, the day 1 scheduling should be made non-cyclical (as the day 8 will need to be) but scheduled on every cycle. |
| VALIDATOR: CLICK ON THE “LIST” BUTTON ON THE RIGHT AND CHECK THAT THE EVENT LIST IS DISPLAYING CORRECTLY. THIS LIST WILL SHOW YOU HOW EACH DRUG IS SCHEDULED FOR THIS REGIMEN. SELECTING “CYCLICAL” WILL BRING UP LIST OF ALL AGENTS THAT HAVE BEEN SCHEDULED CYCLICALLY. SELECTING “NON-CYCLICAL” WILL BRING UP LIST OF ALL AGENTS THAT HAVE BEEN SCHEDULED NON-CYCLICALLY. TAKE A SCREENSHOT OF THE LIST(S) AND SEND TO THE KMCC SYSTEM ADMINISTRATOR AND ADMINISTRATOR. THIS LIST WILL THEN BE SENT TO THE VALIDATING NURSE FOR REFERENCE | |
| SELECT OK TO COMPLETE THE SCHEDULING FOR THE AGENT THEN REPEAT POINT 5 AS NECESSARY UNTIL ALL REQUIRED AGENTS HAVE BEEN SCHEDULED THEN SELECT CLOSE TO RETURN TO THE PLAN AGENDA | |
|  | **TESTS: THIS WILL BE LEFT BLANK.** |
|  | **TOXICITIES: THIS WILL BE LEFT BLANK.** |
|  | **TREATMENT MANAGEMENT RULES (SUPPORT REGIMENS ONLY): THIS WILL BE LEFT BLANK** |
| SELECT PLAN DETAILS THEN SUMMARY | |
|  | **PLAN SUMMARY WINDOW** |
| **9.1.** | Enter a plan summary to include the following:   * Regimen name and indication * Treatment intent * Treatment drugs, doses, routes and days, * Cycle length and course duration * Details of previous or subsequent regimens if complete treatment not in a single regimen * Signpost to full protocol * Reference(s) document name, version and owner, or website link and date accessed * Change control form number (if applicable)   Clinical Trial regimens should specify the following:  • Trial name with clinical trial suffix-Arm name (if applicable)-regimen name  • Trial Protocol version the regimen has been built from  • EudraCT number or ISRCTN number for the trial  • Protocol long title  • Protocol short title  • IMP drug names, doses, frequency and routes  • Cycle length and duration of treatment for the individual regimen  • Intent for use – a summary of the purpose of the regimen e.g. to assess efficacy and safety of arm A vs arm B |
| **10.** | **PLAN ACCESS WINDOW: SELECT “PLAN DETAILS” THEN “ACCESS” FROM THE MENU AT THE TOP OF THE SCREEN. THIS WINDOW WILL ALLOW YOU TO SPECIFY WHO AND WHERE WILL HAVE ACCESS TO THE REGIMEN THAT YOU HAVE BUILT:** |
| **10.1.** | **Institutions tab**: Select either the “TEST LOCATION – OUTPATIENT” location for adult regimens or “TWH Paed – TEST LOCATION” for paediaric regimens. |
| **10.2.** | **Users tab:** Leave all users un-ticked |
| **11.** | **APPROVE PLAN: SELECT APPROVE FROM THE TOOLBAR THEN THE ANALYSE BUTTON AT THE BOTTOM OF THE SCREEN TO CHECK FOR ANY ERRORS IN THE SET-UP. IF NO PROBLEMS ARE HIGHLIGHTED, CLICK ON THE APPROVE FOR TESTING BUTTON.** |
| **BUILDER:** TEST YOUR REGIMEN IN MANAGER BY ORDERING FOR A TEST PATIENT – SEE GUIDE - THEN COMPLETE THE ARIA BUILDING CHECKLIST AND SUBMIT TO THE VALIDATING PHARMACIST | |
| **VALIDATING PHARMACIST:** INFORM THE KMCC ADMINISTRATOR THAT THE VALIDATION CAN NOW BE SENT TO THE CONSULTANT. IF THE REGIMEN BEING VALIDATED IS A SUPPORT REGIMEN THAT WILL BE USED IN COMBINATION WITH A CHEMO REGIMEN, INFORM THE KMCC ADMINISTRATOR WHO WILL FACILITATE ACCESS | |

|  |  |
| --- | --- |
| **PHARMACIST VALIDATION** | |
| **ARIA MANAGER** | |
| **LOG INTO ARIA MANAGER AT “TEST LOCATION - OUTPATIENT” LOCATION FOR ADULT REGIMENS OR “TWH PAED – TEST LOCATION” FOR PAEDIARIC REGIMENS. CREATE A TEST PATIENT (SEE KMCCEP012 ARIA TEST PATIENT SET UP GUIDE). ENTER VITAL SIGNS FOR THE LARGE PATIENT THEN OPEN THE MEDICATIONS WINDOW** | |
| 1. **FOR CHEMOTHERAPY REGIMENS**: SELECT THE RELEVANT CANCER DISEASE SITE FOR THE REGIMEN THAT YOU WILL BE TESTING AND HIGHLIGHT THE REGIMEN. CONTINUE TO POINT 12. 2. **FOR SUPPORT REGIMENS USED IN COMBINATION WITH A CHEMOTHERAPY REGIMEN**: SELECT THE SAME CHEMOTHERAPY REGIMEN AS SET UP FOR THE CONSULTANT FROM THE RELEVANT DISEASE SITE FOLDER AND ORDER, THEN FOLLOW POINT c) BELOW. THE FOLLOWING TESTS NEED ONLY BE PERFORMED ON THE SUPPORT REGIMEN DRUGS 3. **FOR SUPPORT REGIMENS USED AS A STAND-ALONE TREATMENT**: GO TO ORDERS/RX TAB THEN SELECT ‘NEW’ BUTTON. FROM THE NEW PRESCRIPTION WINDOW COMPLETE THE “ORDERED BY” FIELD BY SELECTING DR. MD VARIAN THEN SELECT THE FAVORITES BUTTON, SELECT “SUPPORT” THEN CLICK ONCE ON THE REQUIRED PLAN. GO TO POINT 13. | |
| **12.** | **CHEMOTHERAPY REGIMENS – START TREATMENT TAB** |
| **12.1.** | Check that the regimen appears in the correct folder(s) in Manager based on the indication specified in the treatment protocol, e.g. lung 🡲 NSCLC etc.  **For Clinical Trials ensure that the regimen appears in the correct Clinical Trial dropdown for the disease being selected.** |
| **12.2.** | Next to the drop-down menu bar check that the cycle length is correct. |
| **12.3.** | Check that the standard number of cycles is correct |
| **13.** | **SUPPORT REGIMENS – FAVORITE AGENTS SELECTION** |
| **13.1.** | Check that the support regimen appears in the correct folder |
| **13.2.** | Next to the support regimen name, check that the cycle length is correct |
| **13.3.** | Check that the standard number of cycles is correct |
| ORDER YOUR REGIMEN FOR THE TEST PATIENT. IF CYCLE 1 CONTAIN S MULTIPLE TREATMENT DAYS, ALL DAYS SHOULD BE ORDERED | |
| **14.** | **DOSE CALCULATION MANAGEMENT WINDOW (If there are no calculated doses (flat dose only) with NO permitted dose reductions, omit test 14)** |
| **14.1.** | For regimens with calculated doses, check that the BSA is capped in the Dose Calculation Management window. This window should automatically open when you first order the regimen. If it does not, then click on the icon in the top right-hand corner. |
| **14.2.** | Uncap the BSA by selecting ‘Use Actual’ |
| FOR EACH OF THE INDIVIDUAL AGENTS IN THE REGIMEN, CHECK THE FOLLOWING:  (NB: If a support regimen is prescribed in combination with an approved chemotherapy regimen, only the agents in the support regimen should be checked) | |
| **15.** | **REVIEW PRESCRIPTION DETAILS WINDOW** |
| **15.1.** | Are all the agents still in the correct administration sequence as shown in Planner? For regimens with more than one scheduled treatment day, all ‘Internal’ agents are listed first, followed by all ‘Pickup - Internal’ agents. |
| **15.2.** | Are all the agents correct in terms of routes of administration, diluents, infusion volumes and durations? |
| **15.3.** | For each agent click on the Administration Instructions box and check that the administration instructions are correct |
| **15.4.** | Are all the doses that have been calculated by the system based on either BSA/weight/CrCl etc. correct and match what is specified in the regimen and set up in Planner. For Clinical Trials ensure that any regimens built with edited dose calculations are correct and match what is setup in the planner. |
| **15.5.** | If any of the drugs are dose banded or rounded, check that the dose is as expected”. The dose banding table can be viewed by clicking on the  icon. |
| **TAKE A SCREENSHOT OF THE REGIMEN AT 100% dose and actual BSA** | |
| **CLICK ON THE  ICON IN THE TOP RIGHT-HAND CORNER AND SELECT ‘USE CAP’ TO APPLY TO 2M² DOSE CAP** | |
| HIGHLIGHT AN AGENT AND CLICK ON THE ‘ADJUST DOSE’ BUTTON AND CHECK THAT THE APPROPRIATE DOSE BANDING OR ROUNDING HAS BEEN APPLIED. If A maximum dose has been specified in the drug entry in Planner, this may override the dose banding. Document any discrepancy on the validation form. | |
| APPROVE THE PRESCRIPTION BY CLICKING ON THE ‘APPROVE ALL’ BUTTON AT THE BOTTOM OF THE SCREEN (THE BLANK DROPDOWN BOXES AT THE TOP OF THE WINDOW NEED TO BE POPULATED FIRST. USE DR MD VARIAN FOR ‘ORDERED BY’). CHECK EACH WINDOW THAT POPS UP DURING THE PRESCRIPTION APPROVAL STAGE. | |
| **16.** | **APPROVAL POP-UP WINDOWS (If applicable. Doesn’t appear for all regimens)** |
| **16.1.** | **First databank interaction screening window:** Check that the Summary tab in the window lists all agents built into the regimen. Any agents excluded from the screening process will have the symbol  next to their name. This is expected for NB notes, but if any drugs have the symbol next to their name, please document on **KMCCEP016 ARIA adult regimen validation and sign-off**. Note: It is not necessary to check the clinical accuracy of the screening information. Click on the Accept button once you have checked the Summary tab. |
| **16.2.** | **Prescription Approval/Printing window** appears, check that all of the information is correct then click the Approve button. |
| PHARMACY APPROVE THE ORDER BY CLICKING ON THE ‘APPROVE’ BUTTON ON THE RIGHT, TICKING THE BOX FOR THE APPROPRIATE ORDER, THEN CLICKING APPROVE AGAIN. | |
| CLICK ON THE ‘DISPENSE’ BUTTON ON THE RIGHT HAND SIDE OF THE SCREEN IN THE ORDERS/RX TAB. | |
| **17.** | **PRESCRIPTION DISPENSING WINDOW** |
| **17.1.** | Check all the information in the Prescription Dispensing window is correct. |
| **17.2.** | All agents are listed. |
| **17.3.** | Are all agents marked correctly as Internal or Pickup - Internal? |
| **17.4.** | Are all agents to be dispensed in Aseptics correctly marked to indicate this? |
| CLICK ON THE BLUE  ICON IN THE TOP LEFT-HAND CORNER OF THE DISPENSING WINDOW TO HIGHLIGHT ALL DRUGS, THEN CLICK ON THE ‘DISPENSE’ BUTTON AT THE BOTTOM OF THE WINDOW, AND THEN CLICK ON ‘APPROVE’. | |
| CLOSE THE DISPENSING WINDOWS AND RETURN TO ORDERS/RX. HIGHLIGHT THE APPROPRIATE ORDER THEN SELECT THE PRINTER SYMBOL. TICK TO PRINT INTERNAL, PICK-UP INTERNAL (AS APPROPRIATE) AND PRINT ADMINISTRATION INSTRUCTIONS AND PRINT TO PDF. CHECK THE DOCUMENTS AND SUBMIT WITH OTHER VALIATION PAPERWORK | |
| CLOSE THE DISPENSING WINDOW THEN CLICK ON THE ‘DRUG ADMIN’ BUTTON ON THE TOOLBAR TO ACCESS THE NURSING SCREEN.  IF THE REGIMEN INCLUDES INTERNAL AGENTS THEN CLICK ON THE DAILY ADMINISTRATION TAB AND CONTINUE TO POINT 18  IF THE REGIMEN CONTAINS ONLY PICK-UP INTERNAL AGENTS CLICK ON THE OTHER ADMINISTRATION TAB AND GO TO POINT 19 | |
| **18.** | **DAILY ADMINISTRATION TAB** |
| **18.1.** | Are all the Internal agents listed in the correct sequence for administration? |
| **18.2.** | If the regimen includes Internal agents being given on different days in the cycle check that the drug is listed under each appropriate date in the Admin Date box. |
| **19.** | **OTHER ADMINISTRATION TAB** |
| **19.1** | Are all the Pick-up Internal agents listed? (they will be in alphabetical order per treatment day) |
| IF THE REGIMEN CONSISTS OF CYCLES SET UP DIFFERENTLY (E.G. FEC-T), EACH DIFFERENT CYCLE MUST BE TESTED BY REPEATING SECTIONS 14 ONWARDS | |
| COMPLETE **KMCCEP016 ARIA adult and paediatric regimen validation and sign-off** AND RETURN TO SYSTEM ADMINISTRATOR | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Regimen name** | Click or tap here to enter text. | **Regimen version** |  | **Regimen Date** | **Enter Date** |
| **Test Patient name** | Click or tap here to enter text. | **Cycles to be ordered** | Click or tap here to enter text. | | |
| **References used** | Click or tap here to enter text. | | | | |

|  |
| --- |
| **LOG IN TO ARIA MANAGER AT EITHER THE “TEST LOCATION – OUTPATIENT” LOCATION FOR ADULT REGIMENS OR “TWH PAED – TEST LOCATION” FOR PAEDIATRIC REGIMENS** AND OPEN THE RECORD OF THE TEST PATIENT STATED ABOVE THEN GO TO THE “RX” ICON |
| An agent list and event list will be sent along with the validation paperwork. The list of agents will show how many drugs are in the regimen and the event list will show how often they are scheduled. All drugs must be fully checked on the first occasion that they appear following the steps below. On subsequent occurences, only their scheduling and position in the prescription being correct as per the reference protocol needs to be checked as all other information will remain the same regardless of when it is scheduled. For example, if there is a single gemcitabine drug entry and gemcitabine is scheduled on days 1, 8, 15 & 22 of the cycle, the drug details and admin instructions need to be checked on day 1, then only the scheduling and drug position needs to be checked on day 8, 15 & 22 |

|  |  |  |  |
| --- | --- | --- | --- |
| **ACTION** | | | **🗸 or 🗶** |
| **A.** | Does the regimen appear in the correct folder(s)? | |  |
| **B.** | Next to the drop down menu bar check that the cycle length is correct? | |  |
| **C.** | Is the standard number of cycles correct? | |  |
| **D.** | Do all treatment days appear and are the appropriate drugs listed for each day? | |  |
| **E.** | Click on the Information text box on the right-hand side to open up the Plan Summary window. Check that all of the information is correct and matches the treatment protocol. This should include: Regimen name and indication, treatment drugs, doses, routes and days, treatment intent, cycle length and course duration, references (including change control), signpost to full protocol | |  |
| ORDER THE REGIMEN FOR THE TEST PATIENT, THEN CHECK THE FOLLOWING | | | |
| **F.** | For each drug, are the following details correct, where applicable? Form, Administration route, Frequency, Diluent type and volume, Infusion duration | |  |
| **G.** | Are all doses, flat and calculated, correct according to the protocol? | |  |
| **H.** | If there are any drug-specific administration instructions, check that they are correct by clicking on the Admin instructions | |  |
| COMPLETE THE ‘ORDERED BY’, ‘START ON’ (ENTER TODAY’S DATE), ‘LINE OF TX’, ‘TX INTENT’ AND ‘TX USE’ FIELDS, THEN CLICK ‘APPROVE ALL’ BUTTON TO APPROVE THE TREATMENT CYCLE. | | | |
| **I.** | In the ‘Treatment’ tab, does the approved cycle appear as ordered | |  |
| **J.** | If the cycle consists of multiple treatment days are these scheduled at the correct intervals? | |  |
| IF THE REGIMEN CONSISTS OF CYCLES SET UP DIFFERENTLY EACH DIFFERENT CYCLE MUST BE TESTED BY ORDERING EACH CYCLE AND REPEATING SECTIONS F-J FOR ALL CYCLES SPECIFIED ABOVE | | | |
| **ERRORS/COMMENTS** | | Click or tap here to enter text. | |

|  |  |  |  |
| --- | --- | --- | --- |
| **I confirm that the regimen has passed all required tests** | | | |
| **Validation Completed by** | Click or tap here to enter text. | **Signed** | Click or tap here to enter text. |
| **Designation** | Click or tap here to enter text. | **Date** | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Regimen name** | Click or tap here to enter text. | **Regimen version** |  | **Regimen Date** | **Enter Date** |
| **Test Patient name** | Click or tap here to enter text. | **Cycles to be ordered** | Click or tap here to enter text. | | |
| **References used** | Click or tap here to enter text. | | | | |

|  |
| --- |
| **LOG IN TO ARIA MANAGER AT EITHER THE “TEST LOCATION – OUTPATIENT” LOCATION FOR ADULT REGIMENS OR “TWH PAED – TEST LOCATION” FOR PAEDIATRIC REGIMENS** AND OPEN THE RECORD OF THE TEST PATIENT STATED ABOVE THEN GO TO THE “RX” ICON |
| FOR SUPPORT REGIMENS THAT WILL BE PRESCRIBED WITH A CHEMO REGIMEN, SELECT THE ORDERS/RX TAB, HIGHLIGHT THE PENDING ORDER AND SELECT MODIFY  FOR SUPPORT REGIMENS THAT WILL BE PRESCRIBED ALONE SELECT THE ORDERS/RX TAB THEN ‘NEW’ BUTTON  FROM THE NEW PRESCRIPTION WINDOW COMPLETE THE “ORDERED BY” FIELD BY SELECTING DR. MD VARIAN |

|  |
| --- |
| An agent list and event list will be sent along with the validation paperwork. The list of agents will show how many drugs are in the regimen and the event list will show how often they are scheduled. All drugs must be fully checked on the first occasion that they appear following the steps below. On subsequent occurences, only their scheduling and position in the prescription being correct as per the reference protocol needs to be checked as all other information will remain the same regardless of when it is scheduled. For example, if there is a single gemcitabine drug entry and gemcitabine is scheduled on days 1, 8, 15 & 22 of the cycle, the drug details and admin instructions need to be checked on day 1, then only the scheduling and drug position needs to be checked on day 8, 15 & 22 |

|  |  |  |  |
| --- | --- | --- | --- |
| **ACTION** | | | **🗸 or 🗶** |
| SELECT THE FAVORITES BUTTON, SELECT “SUPPORT” THEN CLICK ONCE ON THE REQUIRED PLAN | | | |
| **A.** | Does the regimen appear in the correct folder(s)? | |  |
| **B.** | Next to the drop down menu bar check that the cycle length is correct? | |  |
| **C.** | Is the standard number of cycles correct? | |  |
| ORDER THE REGIMEN FOR THE TEST PATIENT, THEN CHECK THE FOLLOWING | | | |
| **D.** | For each drug, are the following details correct, where applicable? Form, Administration route, Frequency, Diluent type and volume, Infusion duration | |  |
| **E.** | Are all doses, flat and calculated, correct according to the protocol? | |  |
| **F.** | If there are any drug-specific administration instructions, check that they are correct by clicking on the Admin instructions | |  |
| COMPLETE THE ‘ORDERED BY’, ‘START ON’ (ENTER TODAY’S DATE), ‘LINE OF TX’, ‘TX INTENT’ AND ‘TX USE’ FIELDS, THEN CLICK ‘APPROVE ALL’ BUTTON TO APPROVE THE TREATMENT CYCLE. | | | |
| **G.** | In the ‘Treatment’ tab, does the approved cycle appear as ordered | |  |
| **H.** | If the cycle consists of multiple treatment days are these scheduled at the correct intervals? | |  |
| **I.** | Click on the green pen on the left of the screen next to the support regimen name and select ‘Show Summary’. Check that all of the information is correct and matches the treatment protocol. This should include: Regimen name and indication, Treatment drugs, doses, routes and days,Treatment intent, Cycle length and course duration, References (including change control), Signpost to full protocol | |  |
| IF THE REGIMEN CONSISTS OF CYCLES SET UP DIFFERENTLY EACH DIFFERENT CYCLE MUST BE TESTED BY ORDERING EACH CYCLE AND REPEATING SECTIONS F-J FOR ALL CYCLES SPECIFIED ABOVE | | | |
| **ERRORS/COMMENTS** | | Click or tap here to enter text. | |

|  |  |  |  |
| --- | --- | --- | --- |
| **I confirm that the regimen has passed all required tests** | | | |
| **Validation Completed by** | Click or tap here to enter text. | **Signed** | Click or tap here to enter text. |
| **Designation** | Click or tap here to enter text. | **Date** | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Regimen name** | Click or tap here to enter text. | **Regimen version** |  | **Regimen Date** | **Enter Date** |
| **Test Patient name** | Click or tap here to enter text. | **Cycles to be checked** |  | **Cycles to be administered** |  |
| **References used** | Click or tap here to enter text. | | | | |

|  |
| --- |
| LOG IN TO ARIA MANAGER AT EITHER THE “TEST LOCATION – OUTPATIENT” LOCATION FOR ADULT REGIMENS OR “TWH PAED – TEST LOCATION” FOR PAEDIATRIC REGIMENS AND OPEN THE RECORD OF THE TESTPATIENT STATED ABOVE THEN GO TO THE “RX” ICON |
| NOTE: IF YOU ARE VALIDATING A SUPPORT REGIMEN THAT HAS BEEN ORDERED WITH A CHEMOTHERAPY REGIMEN, THE VALIDATION CHECKS ONLY NEED TO BE COMPLETED ON THE SUPPORT REGIMEN AGENTS |
| An agent list and event list will be sent along with the validation paperwork. The list of agents will show how many drugs are in the regimen and the event list will show how often they are scheduled. All drugs must be fully checked on the first occasion that they appear following the steps below. On subsequent occurences, only their scheduling and position in the prescription being correct as per the reference protocol needs to be checked as all other information will remain the same regardless of when it is scheduled. For example, if there is a single gemcitabine drug entry and gemcitabine is scheduled on days 1, 8, 15 & 22 of the cycle, the drug details and admin instructions need to be checked on day 1, then only the scheduling and drug position needs to be checked on day 8, 15 & 22 |

|  |  |  |  |
| --- | --- | --- | --- |
| **ACTION** | | | **🗸, 🗶 or N/A** |
| OPEN THE DRUG ADMINISTRATION WINDOW AND COMPLETE THE FOLLOWING CHECKS AS APPROPRIATE  FOR CYCLES TO BE ADMINISTERED: COMPLETE STEPS A-G  FOR CYCLES TO BE TESTED: COMPLETE STEPS A-F | | | |
| **DAILY ADMININSTRATION TAB** | | | |
| **A.** | Are all the drugs listed in the correct sequence for administration? | |  |
| **B.** | For each drug, are the following details correct, where applicable? Form, Administration route, Frequency, Diluent type and volume, Infusion duration | |  |
| **C.** | If there are any drug-specific administration instructions, check that they are correct by clicking on the Admin instructions | |  |
| **OTHER ADMINISTRATION TAB** | | | |
| **D.** | Are all the Pick-up Internal (TTO) drugs listed here? (drugs will appear in alphabetical order) | |  |
| **E.** | Check that all drugs have the correct dose, form, route of administration, frequency, infusion rate, diluent information, and administration instructions (where applicable). If there is a stated maximum dose for a drug on the protocol, ensure this is also stated in the admin instructions | |  |
| **F.** | If the regimen includes some Pickup - Internal agents being given on different days, e.g. Vinorelbine oral given on Day 1 and Day 8, check that all days of treatment are listed and that the information is correct, and the drug is being administered on the correct day(s). | |  |
| IN THE “DAILY ADMINISTRATION” AND “OTHER ADMINISTRATION” WINDOWS RECORD EACH AGENT FOR THE CYCLE STATED ABOVE AS ADMINISTERED BY SELECTING EACH AGENT, CLICKING ON THE “RECORD” BUTTON, ENTERING AN ADMINISTRATION TIME AND CLICKING ON THE “APPROVE” BUTTON. | | | |
| **MEDICATION HX TAB** | | | |
| **G.** | Are all of the administered drugs listed in the appropriate sections, i.e. all anti-cancer drugs listed under ‘Active Chemotherapy Agents’ and all other supportive drugs and warning notes listed under ‘Active Non-Chemotherapy Agents’? NB: For support regimens, all agents become ‘Inactive Agents’ immediately after administration | |  |
| **ERRORS/COMMENTS** | | Click or tap here to enter text. | |
| FOR NEW REGIMENS, COMPLETE AND SUBMIT A KOMS NEW EVENT REQUEST FORM | | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **I confirm that the regimen has passed all required tests** | | | |
| **Validation Completed by** | Click or tap here to enter text. | **Signed** | Click or tap here to enter text. |
| **Designation** | Click or tap here to enter text. | **Date** | |